[患有AQP4阳性神经omyelitis光学谱障碍的患者的2型症状性麻醉症]
Takashi Yoshimura1,2, Masakazu Wakai1, Takashi Kanbayashi3,4
1Department of Neurology, Chutoen General Medical Center.
Rinsho shinkeigaku = Clinical neurology
|March 26, 2025
概括
神经omyelitis光学谱系障碍 (NMOSD) 可以表现为麻醉症的症状,即使在正常的素水平. 睡眠研究对于诊断NMOSD患者的2型麻醉症至关重要,特别是当典型的生物标志物缺席时.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 免疫学 免疫学 免疫学
背景情况:
- 多发性硬化症 (MS) 治疗有时会导致意想不到的神经系统并发症.
- 水素-4 (AQP4) 自体抗体是神经omyelitis光学谱障碍 (NMOSD) 的关键生物标志物.
- 麻醉症是一种睡眠障碍,其特点是过度的白天嗜睡和潜在的其他症状,如 kataplexy.
研究的目的:
- 为了调查一个被诊断为2型麻醉症的患者的病例,后来发现患有NMOSD.
- 突出全面睡眠研究在诊断睡眠障碍方面的重要性,特别是在自身免疫性疾病的背景下.
- 要强调的是,正常的脑脊液 (CSF) 素水平并不排除NMOSD患者的麻醉症.
主要方法:
- 一个63岁的女性患者的病例报告分析,她有MS病史.
- 临床评估包括住院治疗昏昏欲睡和昏昏欲睡.
- 诊断程序:腰部穿刺,脑电图 (EEG),多重睡眠延迟测试 (MSLT) 和AQP4自身抗体测试.
- 脑脊液 (CSF) 甲素水平测量. 脑脊液中的甲素水平测量.
主要成果:
- 患者最初出现了暗示2型麻醉症的症状,经MSLT证实,尽管CSF素水平正常.
- 随后的测试显示,该患者对AQP4抗体呈阳性,导致诊断为NMOSD.
- 观察到无症状的病变扩张在丘脑和基底腺,这是NMOSD的特征.
结论:
- 睡眠生理学测试,包括MSLT,对于诊断麻醉症至关重要,即使存在NMOSD.
- 一些NMOSD患者可能不会出现典型的下丘脑病变或与麻醉症相关的CSF素水平降低.
- 这一案例强调了自身免疫性疾病和睡眠障碍之间的复杂相互作用,需要进行彻底的诊断工作.
相关概念视频
Narcolepsy
84
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
84
Sleep-Wake Cycles
1.2K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.2K
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
Myasthenia Gravis: Diagnostic Tests
581
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
581
REM Sleep Behavior Disorder
123
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
123


